This is the authors' abstract. We don't add key points for this paper.
We report the first effort to control the size of polydopamine nanoparticles via adding either strong free radical scavengers ( i.e. edaravone) or stable free radicals ( i.e. PTIO˙) during the polymerization.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: